<DOC>
	<DOCNO>NCT00847899</DOCNO>
	<brief_summary>The purpose study determine safety efficacy AR9281 , novel s-EH enzyme inhibitor , improve glucose metabolism blood pressure patient impair glucose tolerance mild moderate hypertension .</brief_summary>
	<brief_title>Evaluation Soluble Epoxide Hydrolase ( s-EH ) Inhibitor Patients With Mild Moderate Hypertension Impaired Glucose Tolerance</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<criteria>mild moderate hypertension naive antihypertensive medication two less antihypertensive medication impair glucose tolerance mild obesity Diagnosis Type 1 Type 2 diabetes History severe heart failure AST , ALT level twice normal range</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>hypertension</keyword>
	<keyword>impaired glucose tolerance</keyword>
	<keyword>s-EH enzyme inhibition</keyword>
	<keyword>pre-diabetes</keyword>
</DOC>